Dr Tatiana Novobrantseva, Chief Scientific Officer, NextPoint Therapeutics, tells us about the work she’s leading to develop therapies that harness a new and differentiated member of the B7 family, for patients who didn’t see benefit from current checkpoint blockade therapies.
Lead Editorial
